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Abstract 
An improved gradient, reversed-phase liquid chromatographic (RP-LC) method 
was developed and subsequently validated for the determination of Loratadine 
and its impurities/degradation products in pharmaceutical drug substance. 
Separation was achieved with Inertsil ODS-3V, 250 x 4.6 mm, 5μ column with 
gradient elution at a flow rate of 1.0 mL min
−1. UV detection was performed at 
220 nm. The described method is linear over a range of LOQ (0.044, 0.088, 
0.084, and 0.072 µg mL
−1 for impurity-B, impurity-C, impurity-D, and impurity-E 
respectively) to 1.2 µg mL
−1 (0.6 µg mL
−1 of the specification limit) for all the 
impurities and degradation products. The recovery of impurities were found to 
be in the range of 85–115 %. The method is simple, selective, and accurate for 
the quantification of impurities and degradation products of Loratadine in its bulk 
drug samples.  
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Introduction 
Loratadine is a second generation antihistamine drug closely structurally related to tricyclic 
antidepressants such as imipramine, and distantly related to the atypical antipsychotic 
quetiapine, used to treat allergies, which is available in the market as Claritin. Its chemical 
name is ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-
piperidine-1-carboxylate. Claritin is indicated for the relief of nasal and non-nasal 
symptoms of seasonal allergic rhinitis and for the treatment of chronic idiopathic urticaria. 
The pKa of loratadine is 5.0. 
Patients with severe hepatic disorders may need to start with a lower dose. No dose 
adaptation is necessary for elderly or renally impaired patients Loratadine is usually 
compatible with breast-feeding (classified category L-2 by the American Academy of 
Pediatrics). In the U.S., it is classified as category B in pregnancy, meaning that animal 
reproduction studies have failed to demonstrate a risk to the fetus and there are no 
adequate and well-controlled studies in pregnant women.  
Loratadine is given orally, is well absorbed from the gastrointestinal tract, and has rapid 
first-pass hepatic metabolism; it is metabolized by isoenzymes of the cytochrome P450 
system, including CYP3A4, CYP2D6, and, to a lesser extent, several others. Loratadine is 
almost totally (97–99%) bound to plasma proteins. Its metabolite desloratadine is largely 
responsible for the antihistaminergic effects. It binds to plasma proteins by 73–76%. 
Loratadine peak effect occurs in 1–2 hours, and its biological half-life is on average 
8 hours (range 3–20 hours) with desloratadine half-life being 28 hours (range 9–92 hours), 
accounting for its long-lasting effect. About 40% is excreted as conjugated metabolites into 
the urine, and a similar amount is excreted into the feces. Traces of unmetabolized 
loratadine can be found in the urine [1].  
 
Fig. 1.   200 µg mL
−1 of Desloratadine, LRT-II, Deschloro, Bromo, Dehydro impurities 
and 400 µg mL
−1 of Loratadine. 
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Tab. 1.  Name of impurity, chemical structure and chemical name of Loratadine and five 
impurities (Desloratadine, LRT-II, Deschloro, Bromo, Dehydro) 
S.No.  Name of impurity  Structure  IUPAC Name 
1 Loratadine 
N
N
OO
Cl
 
Ethyl 4-(8-chloro-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-
11-ylidene)piperidine-1-carboxylate 
2  Impurity-A  
(Desloratadine) 
N
H
N
Cl
 
8-Chloro-11-piperidin-4-ylidene-
6,11-dihydro-5H-benzo[5,6]cyclo-
hepta[1,2-b]pyridine 
3  Impurity-B 
(LRT-2) 
N
N
Cl
 
8-Chloro-11-(1-methylpiperidin-4-ylidene)-
6,11-dihydro-5H-benzo[5,6]cyclo-
hepta[1,2-b]pyridine 
4  Impurity-C  
(Deschloro) 
N
N
OO  
Ethyl 4-(5,6-dihydro-11H-benzo[5,6]cyclo-
hepta[1,2-b]pyridin-11-ylidene)piperidine-
1-carboxylate 
5  Impurity-D  
(Bromo) 
N
N
OO
Br
 
Ethyl 4-(8-bromo-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-
11-ylidene)piperidine-1-carboxylate 
6  Impurity-E  
(Dehydro) 
N
N
OO
Cl
 
Ethyl 4-(8-chloro-11H-benzo[5,6]cyclo-
hepta[1,2-b]pyridin-11-ylidene)piperidine-
1-carboxylate 280 G.  Ramulu  et al.:  
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Here, we present an improved analytical method for determination of impurities and 
degradation products in Loratadine drug substance, which will serve as a linear and 
accurate for its determination. A zypical chromatogram of all spiked impurities with 
loratadine is displayed in Figure 1. In the method, developed, herein, all the impurities and 
degradation products were well separated from the Loratadine peak. This method has 
been thoroughly validated as per the ICH guidelines. 
Tab. 2.   Working concentration (% and µg mL
−1) of Loratadine impurities and related 
retention time (RRT) with respect to Loratadine are as follow. 
Working concentration  Impurities 
µg mL
−1 % 
RRT 
Impurity-A 0.6  0.15 0.16 
Impurity-B 0.6  0.15 0.23 
Impurity-C 0.6  0.15 0.73 
Impurity-D 0.6  0.15 1.06 
Impurity-E 0.6  0.15 1.21 
 
Results and Discussion 
Method development 
In order to develop an improved suitable and robust LC method for the determination of 
Loratadine and its impurities and degradation products, different mobile phases and 
columns were employed to achieve the best separation and resolution. Initially, the 
isocratic method was used to estimation of impurities in Loratadine. Buffer (0.05 M 
monobasic potassium phosphate), Acetonitrile, Methanol and Triethyl amine (38:45:17:0.5 
v/v) adjusted with ortho phosphoric acid to a pH of 3.6. Inertsil ODS-3V, 250 x 4.6 mm, 5μ 
was used for estimating the impurities. Separation was not observed between Impurity-B 
with one of the degradent i.e Impurity-A at about a retention time of 3.2 minutes. In 
addition, less resolution was observed between Impurity-E and Loratadine. Then pH 
increased to slightly 3.2 to 5.0 even though separation was not observed, again increased 
the pH to 6.9 separation was observed between Impurity-B and Impurity-A with 2.5 
resolution but Impurity-E was merged with Loratadine. Thus there is a need to develop a 
robust method to quantify the Impurity-A and impurity-B in Loratadine. Several trials were 
made by using different mobile phase ratios, gradient programmes by varying buffer pH 
between 2 and 8 with C8 and C18 stationery phases. Based on the experimental trials it is 
understood that pH is playing the critical role in the separation between four impurities and 
Loratadine. Established LOD and LOQ for Impurity-A is 0.007% and 0.025% respectively 
in this method so it can also useful for the determination and identification of this impurity. 
Very few methods appeared in the literature for the determination of Loratadine individually 
based on high-performance liquid chromatography (HPLC) [2–7]. 
Finally, the mobile phase-A contained buffer (0.05 M monobasic potassium phosphate), 
Acetonitrile, Methanol and Triethyl amine (38:45:17:0.5 v/v) adjusted with ortho phosphoric 
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phosphate), Acetonitrile, Methanol and Triethyl amine (38:45:17:0.5 v/v) adjusted with 
ortho phosphoric acid to a pH of 3.6.The flow rate of the mobile phase was 1.0 mL min
−1. 
Analytical parameters and validation 
After satisfactory development of method it was subject to method validation as per ICH 
guideline [8, 9]. The method was validated to demonstrate that it is suitable for its intended 
purpose by the standard procedure to evaluate adequate validation characteristics (system 
suitability, accuracy, precision, linearity, robustness, ruggedness, solution stability, LOD 
and LOQ and stability indicating capability). 
Precision 
The precision of the determination of the impurities was checked by injecting six individual 
preparations of (400 µg mL
−1) Loratadine spiked with 0.6 μg mL
−1 of impurity-B, impurity-C, 
impurity-D and impurity-E and calculating the % RSD of % area for each compound. The 
intermediate precision of the method was also evaluated using different day and different 
instrument in the same laboratory are shown in Table 3 and 4. 
Tab. 3.   Results of method precision 
Preparation Impurity-B Impurity-C Impurity-D Impurity-E 
Prep-1 0.16  0.11 0.16 0.34 
Prep-2 0.17  0.12 0.17 0.35 
Prep-3 0.16  0.11 0.16 0.35 
Prep-4 0.16  0.11 0.16 0.34 
Prep-5 0.16  0.11 0.16 0.34 
Prep-6 0.16  0.11 0.16 0.35 
%RSD  1.4 1.5 0.5 2.3 
 
Tab. 4.   Results of intermediate method precision 
Preparation Impurity-B Impurity-C Impurity-D Impurity-E 
Prep-1 0.16  0.11 0.16 0.34 
Prep-2 0.17  0.12 0.17 0.35 
Prep-3 0.16  0.11 0.16 0.35 
Prep-4 0.16  0.11 0.16 0.34 
Prep-5 0.16  0.11 0.16 0.34 
Prep-6 0.16  0.11 0.16 0.35 
  %RSD  2.5 3.6 2.5 1.5 
 
Limit of detection and Limit of quantification  
Sensitivity was determined by establishing the limit of detection (LOD) and limit of 
quantification (LOQ) for impurity-B, impurity-C, impurity-D and impurity-E estimated at a 
signal to noise ratio of 3:1 and 10:1 respectively, by injecting a series of dilute solutions 
with known concentration. The limit of detection of a compound is defined as the lowest 282 G.  Ramulu  et al.:  
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concentration that can be detected. LOD values were found to be 0.016, 0.028, 0.024, and 
0.020µg mL
−1 for impurity-B, impurity-C, impurity-D, and impurity-E respectively. The limit 
of quantification is the lowest concentration of a compound that can be quantified with 
acceptable precision and accuracy. LOQ values were found to be 0.044, 0.088, 0.084, and 
0.072 µg mL
−1  for impurity-B, impurity-C, impurity-D, and impurity-E respectively. The 
precision study was also carried out at the LOQ level by injecting six individual 
preparations of impurity-B, impurity-C, impurity-D, and impurity-E and calculating the % 
RSD for the areas of each impurity are shown in Table 5. 
Tab. 5.   Results of LOQ precision 
Preparation  Impurity-B Impurity-C Impurity-D Impurity-E 
Prep-1  15812 11794 14659 26316 
Prep-2  13658 12441 13550 25596 
Prep-3  13969 12384 13770 26156 
Prep-4  16232 12115 14672 26484 
Prep-5  13995 12389 14635 25672 
Prep-6  14087 12391 13657 25900 
%RSD   7.5   2.1   3.9  1.4 
 
Linearity 
Standard solutions at eight different concentration levels ranging from LOQ (0.044, 0.088, 
0.084, and 0.072 µg mL
−1 for impurity-B, impurity-C, impurity-D, and impurity-E 
respectively) to 1.2 μg mL
−1 (0.60 μg mL
−1 of specification limit) were prepared and 
analyzed in order to demonstrate the linearity for all the impurities. Linearity regression 
analysis demonstrated acceptability of the method for quantitative determination range of 
LOQ (0.044, 0.088, 0.084, and 0.072 µg mL
−1 for impurity-B, impurity-C, impurity-D, and 
impurity-E respectively) to 1.2 μg mL
−1 of specification limit. The coefficient of correlation 
was found to be more than 0.995. The linearity results are shown in Table 6a and 6b. 
Tab. 6a.   Linearity results 
Conc. µg  Impurity-B  Impurity-C  Impurity-D Impurity-E 
LOQ 16359  12229  36205  64190 
0.15 37524  24050  47599  100585 
0.30 54121  37833  61747  132200 
0.45 82057  54758  79606  174929 
0.60 108804  68981  93864  205192 
0.75 127788  87254  112811  249905 
0.90 150620  102170  128301  282397 
1.20 189488  136298  165058  375571 
R
2 0.998  0.999  0.999  0.998 
LOQ values were 0.044, 0.088, 0.084 and 0.072 µg mL
−1 for impurity-B, impurity-C, 
ii t Dd i i t E ti l
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Tab. 6b.   Correlation coefficient (R
2), slope and y-intercept results for impurity-B, impurity-
C, impurity-D, and impurity-E. 
  Impurity-B Impurity-C Impurity-D Impurity-E 
R
2  0.998 0.999 0.999 0.998 
Slope 150956.4  108938.6  112880  264570.9 
Y-Intercept 12932.3  5013.0  28085.1  51879.6 
 
Accuracy  
Accuracy of the method was demonstrated at four different concentration levels in 
triplicate. The analysis carried out at 0.30, 0.45, 0.60 and 0.90 µg mL
−1 of specification 
limit. The mean recoveries of all the impurities were found to be in the range of 85-115 % 
as shown in Table 7. Typical chromatogram for all spiked impurities at 0.30, 0.45, 0.60 and 
0.90 µg mL
−1 with Loratadine is displayed in Figure 2, 3, 4 and 5 respectively. 
Tab. 7.  Accuracy results 
Conc. µg mL
−1 Impurity-B(%) Impurity-C(%) Impurity-D(%) Impurity-E(%) 
0.30  100.6 101.1 102.6 100.1 
0.45  101.1 101.0 102.5 103.5 
0.60 99.7  100.7  100.7  100.7 
0.90 99.5  99.8  100.6  100.2 
 
 
Fig. 2a.  Typical chromatogram for 0.30 µg mL
−1 of impurity-B, impurity-C, impurity-D 
and impurity-E spiked with Loratadine. 284 G.  Ramulu  et al.:  
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Fig. 2b.   Typical chromatogram for 0.45 µg mL
−1 of impurity-B, impurity-C, impurity-D 
and impurity-E spiked with Loratadine. 
 
Fig. 2c.   Typical chromatogram for 0.60 µg mL
−1 of impurity-B, impurity-C, impurity-D 
and impurity-E spiked with Loratadine. 
 
Fig. 2d.   Typical chromatogram for 0.90 µg mL
−1 of impurity-B, impurity-C, impurity-D 
and impurity-E spiked with Loratadine. 
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Robustness 
In order to demonstrate the robustness of the method, system suitability parameters were 
verified by making deliberate changes in the chromatographic conditions, viz, change in 
flow rate from 1 mL min
−1 (Figure 3a) to 0.8 and 1.2 mL min
−1 (Figure 3b and 3c), change 
in pH of the buffer +0.2 unit, change in column temperature from 40°C (Figure 4a) to 35°C 
and 45°C (Figure 4b and 4c) and change the organic phase composition in the mobile 
phase from 100% (Figure 5a) to 90% and 110% (Figure 5b and 5c). The method was 
demonstrated to be robust over an acceptable working range of its HPLC operational 
parameters.  
 
Fig. 3a.  Typical spiked chromatogram for flow rate at 1 mL min
−1. 
 
Fig. 3b.  Typical spiked chromatogram for flow rate at 0.8 mL min
−1. 286 G.  Ramulu  et al.:  
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Fig. 3c.  Typical spiked chromatogram for flow rate at 1.2 mL min
−1. 
 
Fig. 4a.  Typical spiked chromatogram for temperature at 40°C. 
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Fig. 4c.  Typical spiked chromatogram for temperature at 45°C. 
 
Fig. 5a.  Typical spiked chromatogram for organic phase at 100%. 
 
Fig. 5b.  Typical spiked chromatogram for organic phase at 90%. 288 G.  Ramulu  et al.:  
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Fig. 5c.  Typical spiked chromatogram for organic phase at 110%. 
Experimental 
Reagents and Materials 
Samples of Loratadine and its related substances were received from process 
development laboratory of Dr. Reddy’s Laboratories Ltd., IPDO, Hyderabad, India. HPLC 
grade Acetonitrile, Methanol, monobasic potassium phosphate, ortho Phosphoric acid and 
Triethyl amine purchased from Merck, Germany., purchased from Regis technologies Inc, 
USA and high pure water was prepared by using Millipore Milli Q plus purification system.  
Equipment 
The LC system used for method development and method validation was Waters LC 
system with a diode array detector (Model, quaternary gradient). The out put signal was 
monitored and processed using waters millennium software 3.2 version and released is 
March 31 2003.  
Chromatographic system 
The chromatographic column used was Inertsil ODS-3V, 250 x 4.6 mm, 5μ. The mobile 
phase A contained buffer (0.05 M monobasic potassium phosphate), Acetonitrile, 
Methanol and Triethyl amine (38:45:17:0.5 v/v) adjusted with ortho phosphoric acid to a pH 
of 6.9 and mobile phase B consisted buffer (0.05 M monobasic potassium phosphate), 
Acetonitrile, Methanol and Triethyl amine (38:45:17:0.5 v/v) adjusted with ortho phosphoric 
acid to a pH of 3.6.The flow rate of the mobile phase was 1.0 mL min
−1. The LC gradient 
program (Table 8) was set as: time (min)/% mobile phase- B: 0.01/0, 5/0, 9/20, 13/40, 
17/70, 20/90, 25/100, 30/100, 35/70, 40/50, 45/20, 50/0 and 60/0. The column temperature 
was maintained at 40°C and the detection was monitored at a wavelength of 220 nm. The 
injection volume was 50 µL. Mobile phase A was used as diluent for sample preparations.    A New Validated Liquid Chromatographic Method for the Determination of Loratadine and its …  289 
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Tab. 8.  Gradient program 
Time(min)  % Mobile phase-A  % Mobile phase-B  Gradient line 
0.00 100.0  0.0  6 
5.00 100.0  0.0  6 
9.00 80.0  20.0  6 
13.00 60.0  40.0  6 
17.00 30.0  70.0  6 
20.00 10.0  90.0  6 
25.00 0.0  100.0  6 
30.00 0.0  100.0  6 
35.00 30.0  70.0  6 
40.00 50.0  50.0  6 
45.00 80.0  20.0  6 
50.00 100.0  0.0  6 
60.00 100.0  0.0  6 
 
Sample solution preparation 
Weigh accurately 40mg of Loratadine sample into a 100mL volumetric flask, add 50mL of 
diluent and sonicate for 5minutes. Dilute to volume with diluent.  
Method validation 
The proposed method was validated as per ICH guidelines [8, 9]. 
System suitability 
System suitability parameters were measured so as to verify the system performance. In 
the system suitability solution chromatogram resolution between impurity-D and Loratadine 
was measured. In the standard preparation theoretical plates for Loratadine peak was 
measured. Tailing factor for the Loratadine peak in standard preparation was measured. 
This all system suitability parameters covered the system, method and column 
performance. 
Precision 
The precision of the determination of the impurities were checked by injecting six individual 
preparations of (400 µg mL
−1) Loratadine spiked with 0.60 µg mL
−1 of Impurity-B, Impurity-
C, Impurity-D and Impurity-E and calculating the % RSD of area for each compound. The 
intermediate precision of the method was also evaluated using different analysts and a 
different instrument in the same laboratory.  
Accuracy 
Accuracy of the determination of the impurities were carried out in triplicate at 0.30, 0.45, 
0.60 and 0.90 µg mL
−1 of the Loratadine concentration (400 µg mL
−1).The percentages 
recoveries for the impurities were calculated.  
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Limit of detection (LOD) and Limit of quantification (LOQ)  
The LOD and LOQ for Impurity-A, Impurity-B, Impurity-C, Impurity-D and Impurity-E were 
estimated at a S/N of 3:1 and 10:1 respectively, by injecting a series of dilute solutions with 
known concentrations. Precision study was also carried at the LOQ level by injecting six 
individual preparations of Impurity-B, Impurity-C, Impurity-D and Impurity-E and calculated 
the %RSD for the areas.  
Linearity  
Linearity of test solutions was prepared from stock solution at eight concentration levels 
from LOQ (0.044, 0.088, 0.084 and 0.072 µg mL
−1 for impurity-B, impurity-C, impurity-D, 
and impurity-E respectively) to 1.20 µg mL
−1 of analyte concentration. The peak area 
versus concentration data were subjected to least-squares linear regression analysis. The 
calibration curve was drawn by plotting impurities areas injections against the 
concentration expressed in percentage.  
Robustness  
To determine robustness, experimental conditions were purposely altered and the tailing 
and theoretical plates for Loratadine peak was evaluated.  
To study the effect of flow rate on the tailing and theoretical plates for Loratadine peak, it 
was changed from 1 mL min
−1 to 0.8 and 1.2 mL min
−1 (Refer figure 3a, 3b, 3c). The effect 
of pH on the tailing and theoretical plates for Loratadine peak of the impurities was also 
studied by varying the pH of mobile phase-A from 6.7 to 7.1.The effect of column 
temperature on the tailing and theoretical plates for Loratadine peak, it was changed from 
40°C to 35°C and 45°C (Refer figure 4a, 4b, 4c). In all the above conditions, the 
components of the mobile phase were held constant.  
Conclusion 
The present paper describes the development of a new HPLC method for the 
determination of impurities in Loratadine drug substance and its validation. The method 
was found to be selective, sensitive, precise and accurate for the determination of 
impurities and degradation products. This method can be used for the routine 
determinations in pharmaceutical quality control laboratories. 
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